BSE Live
Apr 01, 16:01Prev. Close
5946.55
Open Price
6095.00
Bid Price (Qty.)
5850.00 (6)
Offer Price (Qty.)
5906.95 (1)
NSE Live
Apr 01, 15:52Prev. Close
5947.00
Open Price
6002.00
Bid Price (Qty.)
5906.50 (59)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Divis Laboratories (in Rs. Cr.) | Mar 05 | Mar 04 | |
| Per Share Ratios | |||
| Basic EPS (Rs.) | 51.51 | 56.83 | |
| Diluted EPS (Rs.) | 51.51 | 56.83 | |
| Cash EPS (Rs.) | 63.27 | 67.16 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 221.29 | 178.80 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 221.29 | 178.80 | |
| Dividend / Share(Rs.) | 8.00 | 8.00 | |
| Revenue from Operations/Share (Rs.) | 278.04 | 244.33 | |
| PBDIT/Share (Rs.) | 93.99 | 91.40 | |
| PBIT/Share (Rs.) | 82.24 | 81.07 | |
| PBT/Share (Rs.) | 79.81 | 79.52 | |
| Net Profit/Share (Rs.) | 51.51 | 56.83 | |
| Profitability Ratios | |||
| PBDIT Margin (%) | 33.80 | 37.41 | |
| PBIT Margin (%) | 29.57 | 33.18 | |
| PBT Margin (%) | 28.70 | 32.54 | |
| Net Profit Margin (%) | 18.52 | 23.25 | |
| Return on Networth / Equity (%) | 23.27 | 31.78 | |
| Return on Capital Employed (%) | 21.16 | 28.20 | |
| Return on Assets (%) | 14.53 | 18.96 | |
| Total Debt/Equity (X) | 0.23 | 0.29 | |
| Asset Turnover Ratio (%) | 78.45 | 81.52 | |
| Liquidity Ratios | |||
| Current Ratio (X) | 1.91 | 1.68 | |
| Quick Ratio (X) | 0.93 | 0.83 | |
| Inventory Turnover Ratio (X) | 2.56 | 2.91 | |
| Dividend Payout Ratio (NP) (%) | 15.53 | 14.07 | |
| Dividend Payout Ratio (CP) (%) | 12.64 | 11.91 | |
| Earnings Retention Ratio (%) | 84.47 | 85.93 | |
| Cash Earnings Retention Ratio (%) | 87.36 | 88.09 | |
| Valuation Ratios | |||
| Enterprise Value (Cr.) | 1,337.96 | 1,915.84 | |
| EV/Net Operating Revenue (X) | 3.75 | 6.12 | |
| EV/EBITDA (X) | 11.10 | 16.35 | |
| MarketCap/Net Operating Revenue (X) | 3.58 | 5.93 | |
| Retention Ratios (%) | 84.46 | 85.92 | |
| Price/BV (X) | 4.50 | 8.10 | |
| Price/Net Operating Revenue | 3.58 | 5.93 | |
| Earnings Yield | 0.05 | 0.04 |
25.02.2026
Divis Labs Consolidated December 2025 Net Sales at Rs 2,604.00 crore, up 12.29% Y-o-Y
25.02.2026
Divis Labs Standalone December 2025 Net Sales at Rs 2,578.00 crore, up 12.23% Y-o-Y
12.02.2026
Accumulate Divis Laboratories; target of Rs 6850: Prabhudas Lilladher
20.11.2025
Accumulate Divis Laboratories; target of Rs 6795: Deven Choksey
25.02.2026
Divis Labs Consolidated December 2025 Net Sales at Rs 2,604.00 crore, up 12.29% Y-o-Y
25.02.2026
Divis Labs Standalone December 2025 Net Sales at Rs 2,578.00 crore, up 12.23% Y-o-Y
14.11.2025
Divis Labs Consolidated September 2025 Net Sales at Rs 2,715.00 crore, up 16.12% Y-o-Y
12.11.2025
Divis Labs Standalone September 2025 Net Sales at Rs 2,660.00 crore, up 15.55% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill
02.04.2026
01.04.2026
Buy Granules India; target of Rs 800: Emkay Global Financial
01.04.2026
Granules India shares up 2% after arm gets VAI status post USFDA inspection
01.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth